DOP050. The efficacy of vedolizumab by disease activity and prior tumour necrosis factor-alpha antagonist failure in patients with ulcerative colitis or Crohn’s disease: post-hoc analyses from the GEMINI 1 and GEMINI 2 studies
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.